ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers (Uridine-GABA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01261260
Recruitment Status : Completed
First Posted : December 16, 2010
Last Update Posted : December 16, 2010
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by:
Mclean Hospital

Brief Summary:

On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those indicating GABA-ergic effects following 14 day pyrimidine administration, the purpose of this study is to assess our following hypotheses:

  1. Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males;
  2. Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase NTP levels in a sample of healthy, unmedicated adult males; and
  3. Brain GABA levels will be directly correlated to high energy phosphate levels in this sample of healthy, unmedicated adult males.

Condition or disease Intervention/treatment Phase
Healthy Male Subjects Drug: Uridine Phase 1

Detailed Description:

Based on prior MRS studies by our group as well as the work of others, we hypothesize that oral administration of uridine will actuate an increase in brain gamma-amino butyric acid (GABA) levels, along with beta-nucleotide triphosphate (ß-NTP) levels, as compared with baseline. Our aim is to investigate this specific neuropharmacological effect and to demonstrate the suitability of a novel magnetic resonance spectroscopy protocol in so doing. Our rationale includes the consideration that the clinical utility of an intervention demonstrably effective in elevating brain GABA and high energy phosphate levels is broad, since lowered GABA and bioenergetic states are associated with a plurality of affective, anxiety, and substance use disorders.

On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those noting GABA-ergic effects of 14 day pyrimidine administration, we hypothesize that an oral dose of 2g of uridine per day for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males. We also hypothesize that this 2g dose of uridine per day for 7 days will increase ß-NTP levels and, further, that the increase in GABA and high energy phosphate levels will be correlated. Of note, the phosphorylation of glutamic acid decarboxylase by ATP significantly increased the activity of this enzyme, which is reponsable for the synthesis of GABA. This choice of time period will allow a determination of time course to efficacy between the acute and extended ranges, and further, because therapeutic dosage levels of uridine have yet to be established, in this and future studies we hope to determine the optimal dosage at which uridine increases brain GABA and ß-NTP levels.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: The Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
Study Start Date : November 2006
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Arm Intervention/treatment
Placebo Comparator: Uridine
1g BID
Drug: Uridine
1 gram tablets BID for 7 days




Primary Outcome Measures :
  1. Using MRI and MRS, after uridine administration an increase in brain GABA and NTP levels will be seen and increases in GABA and NTP will be correlated [ Time Frame: after 7 days of treatment ]
    This choice of time period will allow a determination of time course to efficacy between the acute and extended ranges, and further, because therapeutic dosage levels of uridine have yet to be established, in this and future studies we hope to determine the optimal dosage at which uridine increases brain GABA and ß-NTP levels.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male
  • Age range of 18-60 years
  • BMI between 18.5 and 28
  • Medication-free
  • Capable of providing informed consent
  • Non- smoking for a minimum of one year

Exclusion Criteria:

  • Meets DSM-IV criteria for any Axis I disorder (past or present)
  • Global assessment of functioning (DSM IV TR) less than 50
  • Age less than 18 or greater than 60
  • BMI lower than 18.5 or higher than 28
  • Any history of Alcohol or substance dependence or abuse according to DSM-IV criteria (except for caffeine dependence)
  • Any medical condition which in the opinion of the investigator may have an effect on mood symptoms
  • Any individual who has a current mood disturbance (as defined by DSM-IV-R criteria)
  • Use of cigarettes or other nicotine-containing products
  • Allergy or other contraindication to uridine
  • Individuals unable to comply with instructions or procedures of study
  • History of significant head trauma
  • Claustrophobia or other contraindication to MRI (e.g., pacemaker, metal fragments)
  • Any illicit substance use in the past thirty days
  • Any past treatment for substance abuse
  • Any past hospitalization for mental illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01261260


Locations
United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Mclean Hospital
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Perry F Renshaw, MD PhD The Brain Institute, University of Utah

Responsible Party: Perry F. Renshaw MD PhD, Brain Institute, University of Utah
ClinicalTrials.gov Identifier: NCT01261260     History of Changes
Other Study ID Numbers: 2005-P-002083-McLean
2R01MH058681-04A2 ( U.S. NIH Grant/Contract )
First Posted: December 16, 2010    Key Record Dates
Last Update Posted: December 16, 2010
Last Verified: December 2010

Keywords provided by Mclean Hospital:
uridine
gamma-amino butyric acid
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Proton Echo-Planar Spectroscopic Imaging